United Therapeutics Financial Results
United Therapeutics reported third quarter 2026 total revenues of $832.5 million, a 4% increase year-over-year, driven primarily by growth in Tyvaso DPI and Orenitram sales. Net income for the quarter was $258.6 million, or $5.71 per diluted share, representing a 24% decrease compared to the prior year period.
- Term
- Q3 2026
“United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies designed to exponentially increase the number of patients we can serve.”
Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics
“Our record third quarter revenue performance reflects a business operating at a very high level, driven by strong commercial momentum and focused execution across our organization.”
Michael Benkowitz, President and Chief Operating Officer of United Therapeutics